Market Dashboard

Snapshot View

Interactive Charts

Latest Market Commentary

Market Commentary | September 9th, 2024

Sep 9, 2024

Week in Review... U.S. stock markets experienced a significant downturn this week, marking their worst performance since March 2023: The S&P 500 fell 4.25% for the week The Dow Jones Industrial Average declined by 2.93% The Nasdaq Composite...

Market Commentary | September 3rd, 2024

Sep 3, 2024

Week in Review... Stocks and risk assets ended the week mixed following Federal Reserve Chair Jerome Powell's speech on August 23 at the Jackson Hole Economic Symposium. The S&P 500 edged up 0.24%, marking its fifth consecutive monthly gain The Dow Jones...

Market Commentary | August 26th, 2024

Aug 26, 2024

Week in Review... Stocks and risk assets continued their positive trend as all eyes focused on Jackson Hole and comments from Fed Chair Jerome Powell. The S&P 500 rose 1.45% The Dow Jones Industrial Average increased by 1.27% The Nasdaq Composite finished up 1.40%...

Market Commentary | August 19th, 2024

Aug 19, 2024

Week in Review... Broad equity markets roared higher for the week as investors reacted positive to inflation readings and a stronger-than-expected jobless claims report: The S&P 500 was up 3.93% The Dow Jones Industrial Average increased by 2.94% The Nasdaq...

« Older Entries

Latest Market News from Around the Web

Personal Finance

Charter rolls out new Spectrum pricing and internet speeds, aims to 'be a better service operator'
September 16, 2024
Charter Communications is rolling out new pricing and commitments of reliability as it contends with industry shifts in broadband, TV and mobile businesses.
Boeing freezes hiring in sweeping cost cuts as it grapples with factory worker strike
September 16, 2024
Boeing also said it will pause nonessential staff travel and reduce supplier spending as it deals with a strike by more than 30,000 factory workers.
Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
September 16, 2024
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind Novartis' Pluvicto.
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
September 16, 2024
The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.

Investment

Gold keeps rising to record after record. How to play it from here with options
September 16, 2024
Mike Khouw breaks down a trade in the SPDR Gold shares fund.
Bank of America sees rate cuts propelling gold to $3,000, and this stock is a way to play it
September 16, 2024
Gold prices have been on a tear this year and could rally even higher in 2025 on the back of interest rate cuts, according to Bank of America.
Goldman Sachs sees S&P 500 at 6,000 in 12 months, gives basket to play lower rates
September 16, 2024
'Resilient economic growth should lead to modestly higher bond yields while continued earnings growth drives modestly higher equity prices,' Goldman said.
Investors buying Big Tech stocks and Treasuries ahead of a potential Fed rate cut
September 16, 2024
Frank Holland breaks down what investors are watching as the trader week begins.

Stock Market

Stocks making the biggest moves midday: Nuvalent, Alcoa, Sprouts Farmers Market, Apple and more
September 16, 2024
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest moves before the bell: Apple, Intel, Alcoa, Micron Technology and more
September 16, 2024
These are the stocks posting the largest moves in premarket trading.
Stocks making the biggest moves midday: Moderna, Uber, Boeing, Adobe and more
September 13, 2024
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest moves premarket: Boeing, Oracle, Moderna and more
September 13, 2024
These are the stocks posting the largest moves in premarket trading.

Useful Resources & Links

Check the background of investment professionals on FINRA’s BrokerCheck.

Securities offered through Registered Representatives of Cambridge Investment Research, Inc., a broker-dealer, member FINRA/SIPC. Advisory services through Cambridge Investment Research Advisors, Inc., a Registered Investment Advisor. Cambridge and River City Financial are not affiliated. This communication is strictly intended for individuals residing in the states of AL, FL, KY, ME, NC, NJ, OH, SC, TX, VA, WA, WI and WV. No offers may be made or accepted from any resident outside the specific states referenced.

Cambridge’s Form CRS (Customer Relationship Summary)

The information being provided is strictly as a courtesy. When you link to any of these websites provided herein, River City Financial makes no representation as to the completeness or accuracy of information provided at these sites. Nor is the company liable for any direct or indirect technical or system issues or any consequences arising out of your access to or your use of third-party technologies, sites, information, and programs made available through this site.

River City Financial